As of Jun 22
| +2.98 / +4.41%|
The 20 analysts offering 12-month price forecasts for Gilead Sciences have a median target of 79.00, with a high estimate of 90.00 and a low estimate of 61.00. The median estimate represents a +12.09% increase from the last price of 70.48.
The current consensus among 27 polled investment analysts is to Hold stock in Gilead Sciences. This rating has held steady since June, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.